Literature DB >> 28576974

Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31.

Lita A Freeman1, Stephen J Demosky1, Monika Konaklieva1, Rostislav Kuskovsky1, Angel Aponte1, Alice F Ossoli1, Scott M Gordon1, Ross F Koby1, Kelly A Manthei1, Min Shen1, Boris L Vaisman1, Robert D Shamburek1, Ajit Jadhav1, Laura Calabresi1, Marjan Gucek1, John J G Tesmer1, Rodney L Levine1, Alan T Remaley2.   

Abstract

Lecithin:cholesterol acyltransferase (LCAT) catalyzes plasma cholesteryl ester formation and is defective in familial lecithin:cholesterol acyltransferase deficiency (FLD), an autosomal recessive disorder characterized by low high-density lipoprotein, anemia, and renal disease. This study aimed to investigate the mechanism by which compound A [3-(5-(ethylthio)-1,3,4-thiadiazol-2-ylthio)pyrazine-2-carbonitrile], a small heterocyclic amine, activates LCAT. The effect of compound A on LCAT was tested in human plasma and with recombinant LCAT. Mass spectrometry and nuclear magnetic resonance were used to determine compound A adduct formation with LCAT. Molecular modeling was performed to gain insight into the effects of compound A on LCAT structure and activity. Compound A increased LCAT activity in a subset (three of nine) of LCAT mutations to levels comparable to FLD heterozygotes. The site-directed mutation LCAT-Cys31Gly prevented activation by compound A. Substitution of Cys31 with charged residues (Glu, Arg, and Lys) decreased LCAT activity, whereas bulky hydrophobic groups (Trp, Leu, Phe, and Met) increased activity up to 3-fold (P < 0.005). Mass spectrometry of a tryptic digestion of LCAT incubated with compound A revealed a +103.017 m/z adduct on Cys31, consistent with the addition of a single hydrophobic cyanopyrazine ring. Molecular modeling identified potential interactions of compound A near Cys31 and structural changes correlating with enhanced activity. Functional groups important for LCAT activation by compound A were identified by testing compound A derivatives. Finally, sulfhydryl-reactive β-lactams were developed as a new class of LCAT activators. In conclusion, compound A activates LCAT, including some FLD mutations, by forming a hydrophobic adduct with Cys31, thus providing a mechanistic rationale for the design of future LCAT activators. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28576974      PMCID: PMC5510151          DOI: 10.1124/jpet.117.240457

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

Review 1.  Metabolic and functional relevance of HDL subspecies.

Authors:  Bela F Asztalos; Mariko Tani; Ernst J Schaefer
Journal:  Curr Opin Lipidol       Date:  2011-06       Impact factor: 4.776

2.  Identification of a domain of lecithin-cholesterol acyltransferase that is involved in interfacial recognition.

Authors:  S Adimoolam; A Jonas
Journal:  Biochem Biophys Res Commun       Date:  1997-03-27       Impact factor: 3.575

Review 3.  The Changing Face of HDL and the Best Way to Measure It.

Authors:  Sotirios K Karathanasis; Lita A Freeman; Scott M Gordon; Alan T Remaley
Journal:  Clin Chem       Date:  2016-11-22       Impact factor: 8.327

Review 4.  Idiosyncratic reactions and metabolism of sulfur-containing drugs.

Authors:  Freddi I Zuniga; Danmy Loi; Kah Hiing John Ling; Diane D-S Tang-Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-03-07       Impact factor: 4.481

5.  The high-resolution crystal structure of human LCAT.

Authors:  Derek E Piper; William G Romanow; Ruwanthi N Gunawardane; Preston Fordstrom; Stephanie Masterman; Oscar Pan; Stephen T Thibault; Richard Zhang; David Meininger; Margrit Schwarz; Zhulun Wang; Chadwick King; Mingyue Zhou; Nigel P C Walker
Journal:  J Lipid Res       Date:  2015-07-20       Impact factor: 5.922

6.  Roles of cysteines in human lecithin:cholesterol acyltransferase.

Authors:  S J Qu; H Z Fan; F Blanco-Vaca; H J Pownall
Journal:  Biochemistry       Date:  1993-03-30       Impact factor: 3.162

Review 7.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

8.  Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans.

Authors:  Laura Calabresi; Damiano Baldassarre; Samuela Castelnuovo; Paola Conca; Letizia Bocchi; Chiara Candini; Beatrice Frigerio; Mauro Amato; Cesare R Sirtori; Paola Alessandrini; Marcello Arca; Giuliano Boscutti; Luigi Cattin; Loreto Gesualdo; Tiziana Sampietro; Gaetano Vaudo; Fabrizio Veglia; Sebastiano Calandra; Guido Franceschini
Journal:  Circulation       Date:  2009-08-18       Impact factor: 29.690

9.  Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange.

Authors:  H Czarnecka; S Yokoyama
Journal:  J Biol Chem       Date:  1996-01-26       Impact factor: 5.157

10.  Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol acyltransferase.

Authors:  Alisa Glukhova; Vania Hinkovska-Galcheva; Robert Kelly; Akira Abe; James A Shayman; John J G Tesmer
Journal:  Nat Commun       Date:  2015-03-02       Impact factor: 14.919

View more
  13 in total

Review 1.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

2.  Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol.

Authors:  Kelly A Manthei; Shyh-Ming Yang; Bolormaa Baljinnyam; Louise Chang; Alisa Glukhova; Wenmin Yuan; Lita A Freeman; David J Maloney; Anna Schwendeman; Alan T Remaley; Ajit Jadhav; John Jg Tesmer
Journal:  Elife       Date:  2018-11-27       Impact factor: 8.140

Review 3.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

4.  Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort.

Authors:  Chiara Pavanello; Alice Ossoli; Marcello Arca; Laura D'Erasmo; Giuliano Boscutti; Loreto Gesualdo; Tiziano Lucchi; Tiziana Sampietro; Fabrizio Veglia; Laura Calabresi
Journal:  J Lipid Res       Date:  2020-09-30       Impact factor: 5.922

5.  Controversial Role of Lecithin:Cholesterol Acyltransferase in the Development of Atherosclerosis: New Insights From an LCAT Activator.

Authors:  Cecilia Vitali; Marina Cuchel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-23       Impact factor: 8.311

6.  Interaction of lecithin:cholesterol acyltransferase with lipid surfaces and apolipoprotein A-I-derived peptides.

Authors:  Marco G Casteleijn; Petteri Parkkila; Tapani Viitala; Artturi Koivuniemi
Journal:  J Lipid Res       Date:  2018-02-08       Impact factor: 5.922

Review 7.  Is high-density lipoprotein a modifiable treatment target or just a biomarker for cardiovascular disease?

Authors:  Martin B Whyte
Journal:  JRSM Cardiovasc Dis       Date:  2019-08-12

8.  Positive allosteric modulators of lecithin: Cholesterol acyltransferase adjust the orientation of the membrane-binding domain and alter its spatial free energy profile.

Authors:  Akseli Niemelä; Artturi Koivuniemi
Journal:  PLoS Comput Biol       Date:  2021-03-15       Impact factor: 4.475

9.  HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.

Authors:  Anand Rohatgi; Marit Westerterp; Arnold von Eckardstein; Alan Remaley; Kerry-Anne Rye
Journal:  Circulation       Date:  2021-06-07       Impact factor: 39.918

10.  LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.

Authors:  Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley
Journal:  Pharmacol Res Perspect       Date:  2019-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.